Advertisement

Modelling Human Cytochrome P450-Substrate Interactions

  • D. F. V. Lewis
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 37)

Abstract

The cytochromes P450 (CYP) are extremely important and ubiquitous enzymes, being present in virtually all species studied to date and across the five biological kingdoms where they are associated with the phase I oxidative metabolism of a large number of structurally diverse chemicals, both exogenous and endogenous (Ortiz de Montellano 1995; Ioannides 1996; Lewis 1996, 2001; Rendic and DiCarlo 1997). Of the 1,200 or more P450s sequenced thus far, it has been established that a relatively small number (~10) of the human hepatic enzymes metabolize over 90% of the known drugs in current clinical use, with the CYP2C, CYP2D and CYP3A subfamilies constituting the major catalysts of drug metabolism in man (Rendic and DiCarlo 1997).

Keywords

Lauric Acid Haem Iron Putative Active Site Active Site Amino Acid Residue Nicotinamide Adenine Dinu 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. loannides C (1996) Cytochromes P450: Metabolic and Toxicological Aspects, CRC Press, Boca Raton, FloridaGoogle Scholar
  2. Lewis DFV (1996) Cytochromes P450: Structure, function and mechanism. Taylor and Francis, LondonGoogle Scholar
  3. Lewis DFV (1998) The CYP2 familymodels, mutants and interactions. Xenobiotica 28: 617–661PubMedCrossRefGoogle Scholar
  4. Lewis DFV (1999) Molecular modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate specificity. Exp Toxicol Pathol 51: 369–374PubMedCrossRefGoogle Scholar
  5. Lewis DFV (2000a) Modelling human cytochromes P450 for evaluating drug metabolism: an update. Drug Metab Drug Interact 16: 307–324CrossRefGoogle Scholar
  6. Lewis DFV (2000b) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol 60: 293–306PubMedCrossRefGoogle Scholar
  7. Lewis DFV (2000c) Structural characteristics of human P450 s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 144: 197–203PubMedCrossRefGoogle Scholar
  8. Lewis DFV (2001) A guide to cytochrome p450 structure and function. Taylor and Francis, LondonCrossRefGoogle Scholar
  9. Lewis DFV, Hlavica P (2000) Interactions between redox partners in various cytochrome P450 systems: functional and structural aspects. Biochem Biophys Acta 1460: 353–374PubMedCrossRefGoogle Scholar
  10. Lewis DFV, Pratt JM (1998) The cytochrome P450 catalytic cycle and mecha-nism of oxygenation. Drug Metab Rev 30: 739–786PubMedCrossRefGoogle Scholar
  11. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH (1996) Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica 26: 1067–1086PubMedGoogle Scholar
  12. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27: 319–340PubMedCrossRefGoogle Scholar
  13. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS (1998b) Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chem Biol Interact 115: 175–199PubMedCrossRefGoogle Scholar
  14. Lewis DFV, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS (1999d) Cytochrome P450 substrate specificities, substrate templates and enzyme active site geometries. Drug Metab Drug Interact 15: 1–49CrossRefGoogle Scholar
  15. Lewis DFV, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS (1999b) Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology 133: 1–33PubMedCrossRefGoogle Scholar
  16. Lewis DFV, Lake BG, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS (1999c) Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B 1 and CYP2B4. Xenobiotica 29: 361–393PubMedCrossRefGoogle Scholar
  17. Lewis DFV, Dickins M, Weaver RJ, Eddershaw PJ, Goldfarb PS, Tarbit MH (1998a) Molecular modelling of human CYP2C enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica 28: 235–268PubMedCrossRefGoogle Scholar
  18. Lewis DFV, Bird MG, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS (2000) Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform. Xenobiotica 30: 1–25PubMedCrossRefGoogle Scholar
  19. Lewis DFV, Lake BG, George SG, Dickins M, Eddershaw PJ, Tarbit MH, Beresford AP, Goldfarb PS, Guengerich FP (1999a) Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 139: 53–79PubMedCrossRefGoogle Scholar
  20. Ortiz de Montellano PR (1995) Cytochrome P450. Plenum, New YorkCrossRefGoogle Scholar
  21. Rendic S, DiCarlo FJ (1997) Human cytochrome P450 enzymes: a status re-port summarizing their reactions, substrates, inducers and inhibitors. DrugMetab Rev 29: 413–580CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • D. F. V. Lewis

There are no affiliations available

Personalised recommendations